Santen Pharmaceutical Co., Ltd. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
48,166.00
37,449.00
-3,437.00
37,220.00
12,046.00
32,091.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
5,800.00
15,701.00
-6,460.00
1,854.00
-18,484.00
-392.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
60,928.00
72,649.00
37,147.00
46,043.00
38,808.00
39,947.00
Cash Flow from Investing Activities
-8,223.00
-6,145.00
-26,777.00
-35,169.00
-53,355.00
-5,175.00
Cash Flow from Financing Activities
-53,307.00
-34,031.00
-37,220.00
5,557.00
-16,685.00
-12,729.00
Net Cash Inflow / Outflow
-1,585.00
36,679.00
-25,111.00
20,125.00
-28,542.00
20,633.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
-983.00
4,206.00
1,739.00
3,694.00
2,690.00
-1,410.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in JPY Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Santen Pharmaceutical Co., Ltd.
Figures in Million
consolidated Cash Flow Results
Change(JPY)
Change(%)
Profit Before Tax
48166
3744
44,422.00
1186.49%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
5800
7744
-1,944.00
-25.10%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
60928
25590
35,338.00
138.09%
Cash Flow from Investing Activities
-8223
-154
-8,069.00
-5239.61%
Cash Flow from Financing Activities
-53307
-7921
-45,386.00
-572.98%
Net Cash Inflow / Outflow
-1585
18719
-20,304.00
-108.47%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-983
1204
-2,187.00
-181.64%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -16.13% vs 95.57% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
60,928.00
72,649.00
-16.13%






